Abcam plc (ABCZF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abcam plc (ABCZF) trades at $22.25 with AI Score 46/100 (Grade C). Abcam plc is a global life science company headquartered in the United Kingdom, specializing in the identification, development, and distribution of research reagents and tools. Market cap: $5.12B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ABCZF: ABCZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ABCZF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ABCZF: the 1 perspectives are evenly split.
How is this calculated? →Abcam plc (ABCZF) Healthcare & Pipeline Overview
Abcam plc is a UK-based life science company providing critical research reagents and tools, including antibodies and immunoassays, to academic, pharmaceutical, and biotechnology sectors globally. The company operates an extensive online sales platform, supporting scientific advancements in drug discovery and diagnostics.
What Is the Investment Thesis for ABCZF?
Abcam plc operates as a vital supplier within the global life science research tools market, distinguished by its extensive catalog of antibodies, reagents, and kits essential for biological research, diagnostics, and drug discovery. The company's market capitalization stands at $5.12 billion, reflecting its significant presence in the biotechnology sector. A key value driver is Abcam's strong gross margin of 71.2%, indicating efficient cost management relative to its revenue. While its P/E ratio of 578.4 and profit margin of 1.4% suggest a premium valuation and relatively thin net profitability, this could be attributed to ongoing investments in R&D and market expansion. The company's global operational reach across the Americas, Europe, and Asia Pacific, coupled with its online sales model, provides a broad and accessible distribution network. Growth catalysts include continued innovation in its product portfolio, particularly in emerging research areas, and potential expansion into new diagnostic applications. Investors may want to evaluate the company's ability to maintain its competitive edge through product quality and innovation, alongside managing the inherent risks associated with its OTC Other listing, which implies lower liquidity and less stringent reporting requirements compared to major exchanges.
Based on FMP financials and quantitative analysis
ABCZF Key Highlights
- Market capitalization of $5.12B, positioning Abcam as a significant entity within the biotechnology sector.
- Gross Margin of 71.2%, demonstrating strong profitability at the product level and efficient cost of goods sold.
- Profit Margin of 1.4%, indicating a focus on reinvestment or operational expenses that impact net income despite strong gross margins.
- P/E ratio of 578.4, reflecting a high market valuation relative to its current earnings, potentially due to growth expectations.
- Beta of 0.86, suggesting lower volatility compared to the broader market, offering a degree of stability for investors.
Who Are ABCZF's Competitors?
ABCZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ISEE IVERIC bio, Inc. | $39.95 | +0.38% | $5.51B | 47 |
| ALPN Alpine Immune Sciences, Inc. | $64.97 | +0.02% | $4.46B | 57 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABCZF's Key Strengths?
- Extensive and validated product catalog, particularly in antibodies, crucial for life science research.
- Strong global distribution network facilitated by an effective online sales platform.
- Reputation for product quality and reliability within the scientific community.
- Diversified customer base across academic, pharmaceutical, and biotechnology sectors.
What Are ABCZF's Weaknesses?
- Relatively low profit margin (1.4%) despite a high gross margin, indicating significant operational costs.
- High P/E ratio (578.45) suggests premium valuation, potentially limiting upside without substantial growth.
- Dependence on continuous innovation to maintain competitive edge in a rapidly evolving scientific landscape.
- Operating as an OTC Other stock, which may present challenges regarding liquidity and investor perception.
What Could Drive ABCZF Stock Higher?
- Introduction of novel reagents and tools for emerging research areas, driving product portfolio expansion and market share gains.
- Expansion of the company's global distribution network, particularly in high-growth regions like Asia-Pacific, increasing market reach.
- Strategic partnerships with pharmaceutical or biotechnology companies to integrate Abcam's tools into drug discovery pipelines.
- Continuous improvement and enhancement of the online sales platform, optimizing customer experience and sales efficiency.
- Potential for Abcam's research-grade reagents to be adapted or approved for use in clinical diagnostic applications, opening new market segments.
What Are the Key Risks for ABCZF?
- Rich valuation — a P/E of 578.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Intense competition within the life science research tools market, potentially leading to pricing pressures or market share erosion.
- Rapid technological advancements in biotechnology necessitating continuous R&D investment to maintain product relevance and innovation.
- Fluctuations in global research funding from academic institutions and pharmaceutical companies, impacting demand for research tools.
- Risks associated with the 'OTC Other' listing, including lower liquidity and less stringent reporting requirements, which may affect investor confidence and trading.
- Supply chain disruptions or manufacturing challenges impacting the timely delivery and quality of specialized reagents and antibodies.
What Are the Growth Opportunities for ABCZF?
- **Expansion into Emerging Research Fields:** Abcam can capitalize on the rapid advancements in fields such as gene editing (CRISPR), single-cell analysis, and artificial intelligence-driven drug discovery. By developing and offering specialized antibodies, reagents, and kits tailored to these cutting-edge areas, Abcam can capture new market segments. The global market for gene editing tools alone is projected to reach over $10 billion by the early 2030s, presenting a substantial opportunity for Abcam to innovate and expand its product portfolio, ensuring its tools remain indispensable for researchers pushing scientific boundaries.
- **Deepening Penetration in Asia-Pacific Markets:** The Asia-Pacific region, particularly China, is experiencing significant growth in life science research funding and biotechnology investments. Abcam's existing operations in China and Japan provide a foundation for further expansion. By strengthening its local sales and support infrastructure, and potentially localizing product offerings or establishing strategic partnerships, Abcam can increase its market share in a region where R&D spending is consistently rising. This geographic expansion could unlock substantial revenue growth over the next five to ten years, tapping into a burgeoning scientific community.
- **Leveraging Research Tools for Clinical Diagnostics:** While Abcam primarily focuses on research tools, its high-quality antibodies and immunoassays have potential applications in clinical diagnostics. Collaborating with diagnostic companies or developing its own diagnostic-grade reagents could open access to the much larger and more stable diagnostics market. The global in-vitro diagnostics market is estimated to exceed $100 billion, offering a significant long-term growth avenue. This strategic shift would require navigating different regulatory pathways but could provide a robust revenue stream beyond pure research applications.
- **Strategic Partnerships in Drug Discovery and Development:** Abcam's reagents are fundamental to drug discovery pipelines. Forming deeper strategic partnerships with pharmaceutical and biotechnology companies, offering customized solutions or early access to novel reagents, could embed Abcam more deeply into the R&D process of major players. These collaborations could range from providing bespoke antibody development services to co-developing tools for specific therapeutic areas. Such partnerships could ensure consistent demand for Abcam's products and provide insights into future market needs, securing long-term growth over the next decade.
- **Enhancing Digital Platform and Data Analytics:** Abcam's online sales model is a core strength. Further investment in its e-commerce platform, including advanced search functionalities, personalized recommendations, and integration of AI for customer support, can significantly improve user experience and drive sales efficiency. Additionally, leveraging data analytics from its extensive customer base can inform product development, inventory management, and marketing strategies. A superior digital experience and data-driven operations can reinforce customer loyalty and attract new researchers, maintaining a competitive edge in the digital-first research tools market over the next three to five years.
What Opportunities Does ABCZF Have?
- Expansion into new and emerging research fields like gene editing and single-cell analysis.
- Increased penetration in high-growth geographic markets, especially in Asia-Pacific.
- Potential to leverage research tools for applications in the clinical diagnostics market.
- Strategic partnerships with pharmaceutical companies for drug discovery and development support.
What Threats Does ABCZF Face?
- Intense competition from other research tool providers and in-house development by large institutions.
- Rapid technological obsolescence requiring continuous R&D investment.
- Changes in global research funding or regulatory landscapes impacting demand.
- Risks associated with being an OTC Other stock, including lower liquidity and less stringent reporting.
What Are ABCZF's Competitive Advantages?
- **Extensive Product Catalog:** A vast and continuously updated portfolio of high-quality antibodies and reagents, offering a comprehensive solution for diverse research needs.
- **Global Online Distribution:** A well-established e-commerce platform and global logistics network provide efficient and direct access to customers worldwide.
- **Brand Reputation and Validation:** Known for rigorous product validation and quality control, building trust and reliability among the scientific community.
- **Proprietary Development Capabilities:** In-house expertise in identifying and developing novel reagents, allowing for innovation and differentiation in a competitive market.
- **Customer Data and Insights:** Leveraging data from its online platform to understand researcher needs, inform product development, and optimize customer service.
What Does ABCZF Do?
Abcam plc, incorporated in 1998 and headquartered in Cambridge, the United Kingdom, has evolved into a prominent global life science company. The company's core mission revolves around identifying, developing, and distributing high-quality reagents and tools essential for scientific research, diagnostics, and drug discovery. Initially gaining recognition for its comprehensive catalog of primary and secondary antibodies, Abcam has significantly expanded its product offerings over the years. Today, its portfolio includes a diverse range of conjugated antibodies and conjugation kits, singleplex and multiplex immunoassays, and various proteins and peptides, such as cytokines. Additionally, Abcam supplies edited cell lines and lysates, cellular activity kits, miRNA kits, biochemicals, and specialized cell signaling pathway tools, catering to a broad spectrum of research needs. The company serves a global clientele comprising scientists and researchers within academic institutions, research institutes, and commercial entities, including pharmaceutical, biotechnology, and diagnostics companies. Abcam's operational footprint extends across major regions, encompassing the Americas, Europe, the Middle East, Africa, China, Japan, and the broader Asia Pacific region. A key aspect of its business model is its robust online sales platform, which facilitates efficient product distribution and accessibility for researchers worldwide. This direct-to-customer approach, coupled with a focus on product quality and innovation, has cemented Abcam's position as a critical supplier in the rapidly advancing life sciences research tools market.
What Products and Services Does ABCZF Offer?
- Identify, develop, and distribute a wide range of reagents and tools for life science research.
- Produce primary and secondary antibodies, which are critical for detecting specific proteins in biological samples.
- Offer conjugated antibodies and conjugation kits for various experimental applications.
- Manufacture singleplex and multiplex immunoassays for quantifying proteins and other biomolecules.
- Supply proteins and peptides, including cytokines, essential for cell culture and signaling studies.
- Provide edited cell lines and lysates for genetic and functional research.
- Develop cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
- Sell products globally through an online platform to academic, pharmaceutical, biotechnology, and diagnostics companies.
How Does ABCZF Make Money?
- Develops and manufactures proprietary antibodies and reagents based on scientific demand and innovation.
- Distributes a broad catalog of life science research tools primarily through its e-commerce platform.
- Generates revenue from direct sales of its products to a global customer base of researchers and institutions.
- Focuses on quality control and validation to ensure product reliability, fostering customer loyalty.
- Operates a global supply chain to efficiently deliver products across the Americas, Europe, and Asia Pacific.
What Industry Does ABCZF Operate In?
Abcam plc operates within the dynamic and innovation-driven Biotechnology industry, a sub-sector of Healthcare, which is characterized by continuous scientific advancements and a high demand for specialized research tools. The global life science research tools market is experiencing steady growth, fueled by increasing R&D spending in academic institutions, pharmaceutical companies, and biotechnology firms focused on drug discovery, disease diagnostics, and personalized medicine. Abcam's positioning as a key supplier of antibodies, reagents, and immunoassays places it at the forefront of this market, providing essential inputs for a wide array of biological experiments. The competitive landscape is fragmented, with numerous specialized providers and larger diversified companies. Abcam differentiates itself through its extensive product catalog, quality control, and an efficient online distribution model, catering to a global base of scientists. The industry is also influenced by trends such as the rise of genomics, proteomics, and cell therapy research, which continually create new demands for advanced research tools.
Who Are ABCZF's Key Customers?
- Scientists and researchers in academic institutions and universities.
- Research institutes conducting fundamental and applied biological studies.
- Pharmaceutical companies engaged in drug discovery and development.
- Biotechnology companies focusing on novel therapeutic and diagnostic solutions.
- Diagnostics companies utilizing reagents for clinical testing and assay development.
Company Profile
Abcam plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, GB. The company is led by CEO Markus Lusser. ABCZF has traded publicly since 2011.
Abcam plc (ABCZF) Valuation Context
Valued at $5.12B, ABCZF is classified as a mid-cap stock. Relative to its peer group, ABCZF's quantitative score of 46/100 is below the peer average of 63/100.
ROE 1%Key Financial Metrics
Return on equity for Abcam plc stands at 0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.4%, showing how much profit it generates from its asset base. ABCZF trades at a trailing price-to-earnings ratio of 578.45, above the Healthcare sector average of ~23x. A current ratio of 1.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 9/9Financial Health
Abcam plc's Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.63 places it in the safe zone, indicating low near-term bankruptcy risk.
ABCZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future growth potential.
- Social sentiment has shifted positively, with increased discussions around Abcam's innovative product pipeline.
- Analysts are highlighting the strong demand for biopharmaceutical solutions, which Abcam is well-positioned to capitalize on.
- The company's recent partnerships in the biotech sector have generated excitement among investors, boosting community optimism.
Bear Case
- Concerns over supply chain disruptions have been voiced in community discussions, potentially impacting production timelines.
- Recent earnings reports showed mixed results, leading to skepticism among some investors about future profitability.
- Market perception has been tempered by broader economic uncertainties, causing some traders to adopt a cautious stance.
- Increased competition in the life sciences space has raised red flags, with some analysts warning of potential market share erosion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ABCZF Latest News
No recent news available for ABCZF.
ABCZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABCZF.
Price Targets
Wall Street price target analysis for ABCZF.
ABCZF MoonshotScore
What does this score mean?
The MoonshotScore rates ABCZF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Markus Lusser
Chief Executive Officer
Markus Lusser serves as the Chief Executive Officer of Abcam plc, leading a global workforce of 1760 employees. Prior to joining Abcam, Mr. Lusser held significant leadership roles within the life science and diagnostics industries, accumulating extensive experience in global commercial operations, strategy, and business development. His career trajectory has consistently focused on driving growth and innovation in companies that provide critical tools and services to the scientific community. His background includes a deep understanding of market dynamics in research reagents, instrumentation, and diagnostic solutions, positioning him to guide Abcam's strategic direction.
Track Record: Under Markus Lusser's leadership, Abcam plc has continued to reinforce its position as a key supplier in the life science research tools market. His tenure has been marked by a focus on expanding the company's product portfolio to meet evolving scientific demands and strengthening its global commercial footprint. He has overseen initiatives aimed at enhancing the company's digital platform and operational efficiencies, crucial for serving a worldwide customer base. His strategic decisions have contributed to maintaining Abcam's reputation for quality and innovation in a competitive industry.
ABCZF OTC Market Information
Abcam plc trades on the OTC (Over-The-Counter) market, specifically categorized as 'OTC Other'. This tier represents stocks that do not meet the listing requirements for OTCQX or OTCQB, the higher tiers of the OTC market, nor do they trade on a national exchange like the NYSE or NASDAQ. Companies in the 'OTC Other' tier typically have less stringent reporting requirements and may not provide regular financial disclosures to the same extent as exchange-listed companies. This classification indicates a lower level of transparency and regulatory oversight compared to major exchanges, which can influence investor confidence and market perception.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Lower Liquidity:** Difficulty in buying or selling shares quickly without significantly impacting the price due to fewer buyers and sellers.
- **Limited Information Availability:** Less stringent reporting requirements and potentially 'Unknown' disclosure status can lead to a lack of comprehensive, timely financial information.
- **Price Volatility:** Wider bid-ask spreads and lower trading volumes can contribute to greater price fluctuations.
- **Regulatory Oversight:** Reduced regulatory scrutiny compared to major exchanges may expose investors to higher risks.
- **Market Perception:** The 'OTC Other' designation can carry a perception of higher risk among some investors, potentially limiting institutional interest.
- Verify the company's financial statements and annual reports directly from its official corporate website or UK regulatory filings.
- Research the company's management team and their track record through independent sources.
- Assess the company's business model, competitive advantages, and market position thoroughly.
- Examine trading volume and bid-ask spreads to understand potential liquidity challenges.
- Consult with a financial advisor experienced in OTC markets before making investment decisions.
- Understand the specific risks associated with the 'OTC Other' tier and the company's disclosure practices.
- Monitor news and company announcements from official sources for any material developments.
- Established founding year (1998) and headquarters in Cambridge, UK, indicating a long-standing operation.
- Clear business description and product offerings in a specialized, high-value sector (life sciences).
- Global operational presence across multiple continents, suggesting a significant market footprint.
- Known CEO (Markus Lusser) with a background in the life science industry, providing leadership transparency.
- A substantial market capitalization of $5.12B, indicating a well-capitalized entity despite its OTC listing.
ABCZF Healthcare Stock FAQ
What does Abcam plc do?
Abcam plc is a leading global supplier of high-quality life science research tools, headquartered in the United Kingdom. The company specializes in the identification, development, and distribution of a comprehensive range of reagents, primarily antibodies, but also including immunoassays, proteins, peptides, cell lines, and various kits. These products are crucial for scientists and researchers in academic institutions, research institutes, and commercial entities like pharmaceutical, biotechnology, and diagnostics companies. Abcam's tools are utilized across various scientific disciplines for fundamental research, drug discovery, and diagnostic development, with products sold globally through its robust online platform.
What are the main risks for ABCZF?
Investing in ABCZF carries several key risks. The company operates in a highly competitive and rapidly evolving life science research tools market, requiring continuous innovation to maintain its competitive edge. Fluctuations in global research funding or shifts in scientific priorities could impact demand for its products. Furthermore, as an 'OTC Other' stock, ABCZF is subject to risks such as lower trading liquidity, potentially wider bid-ask spreads, and less stringent public disclosure requirements compared to companies listed on major exchanges. This can lead to greater price volatility and challenges for investors seeking timely and comprehensive financial information. Operational risks include potential supply chain disruptions and the need for ongoing quality control in its specialized product manufacturing.
How does Abcam plc maintain its competitive edge in the life sciences research tools market?
Abcam plc maintains its competitive edge through several strategic pillars. Firstly, it boasts an extensive and continuously updated catalog of high-quality antibodies and reagents, validated through rigorous testing, which is critical for scientific reproducibility. This broad portfolio caters to diverse research needs, making it a comprehensive resource for scientists. Secondly, its robust global online distribution platform ensures efficient access and delivery of products to researchers worldwide, enhancing customer convenience. Thirdly, Abcam focuses on innovation, actively developing new tools for emerging research fields like gene editing and single-cell analysis. Finally, its strong brand reputation, built on product reliability and customer support, fosters loyalty within the scientific community, differentiating it from competitors.
What are the implications of Abcam plc's OTC listing for investors?
Abcam plc's trading on the 'OTC Other' market tier has several implications for investors. This classification generally means lower liquidity, which can make it more challenging to buy or sell shares quickly without impacting the price, potentially leading to wider bid-ask spreads and higher transaction costs. Furthermore, companies in this tier typically have less stringent reporting requirements, and Abcam's disclosure status is 'Unknown,' meaning investors may have limited access to timely and comprehensive financial information. This reduced transparency and regulatory oversight can increase investment risk. Investors must conduct thorough due diligence, relying on the company's official corporate website and UK regulatory filings for information, and be prepared for potentially higher price volatility compared to exchange-listed stocks.
What are the key factors to evaluate for ABCZF?
Abcam plc (ABCZF) holds an AI score of 46/100 (low). P/E: 578.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ABCZF data refresh on this page?
ABCZF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ABCZF's recent stock price performance?
Abcam plc (ABCZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and validated product catalog, particularly in antibodies, crucial for life science research. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABCZF overvalued or undervalued right now?
Abcam plc (ABCZF) trades at 578.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.